Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine:Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies by Ashina, Messoud et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of
Migraine
Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3
Clinical Studies
Ashina, Messoud; Vasudeva, Raghavendra; Jin, Leah; Lombard, Louise; Gray, Elizabeth;
Doty, Erin G.; Yunes-Medina, Laura; Kinchen, Kraig S.; Tassorelli, Cristina
Published in:
Headache
DOI:
10.1111/head.13636
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Ashina, M., Vasudeva, R., Jin, L., Lombard, L., Gray, E., Doty, E. G., ... Tassorelli, C. (2019). Onset of Efficacy
Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2
Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies. Headache, 59(10), 1788-1801.
https://doi.org/10.1111/head.13636
Download date: 27. maj. 2020
1788
Research Submission
Onset of  Efficacy Following Oral Treatment With Lasmiditan 
for the Acute Treatment of  Migraine: Integrated Results  
From 2 Randomized Double-Blind Placebo-Controlled  
Phase 3 Clinical Studies
Messoud Ashina, MD, PhD ; Raghavendra Vasudeva, PhD; Leah Jin, PhD; Louise Lombard, MS;  
Elizabeth Gray, PhD; Erin G. Doty, MD; Laura Yunes-Medina, PhD; Kraig S. Kinchen, MD, MSc;  
Cristina Tassorelli, MD, PhD
Objective.—To expand on available information on the efficacy of oral lasmiditan for the acute treatment of migraine with 
particular focus on the timing of the effect and on its impact on migraine-associated symptoms.
Background.—Lasmiditan is a novel selective 5-hydroxytryptamine 1F receptor agonist that lacks vasoconstrictive activity. 
In 2 phase 3 studies, SAMURAI and SPARTAN, lasmiditan met primary and key secondary efficacy endpoints at 2 hours 
following initial dose.
Methods.—Integrated analyses were completed from 2 phase 3 clinical trials, SPARTAN and SAMURAI. Baseline data 
and data collected every 30  minutes up to 2  hours after taking lasmiditan (50, 100, or 200  mg) or placebo were analyzed to 
determine the onset of efficacy. A total of 5236 patients were randomized to be treated with placebo (N  =  1493), lasmiditan 
50  mg (N  =  750), lasmiditan 100  mg (N  =  1498), or lasmiditan 200  mg (N  =  1495). Data were analyzed to determine the 
onset of improvement for the following efficacy measures: pain freedom, most bothersome symptom freedom, pain relief, freedom 
from associated individual symptoms (photophobia, phonophobia, or nausea), total migraine freedom (defined as pain freedom 
and freedom from associated symptoms), and freedom from migraine-related functional disability. Time to meaningful headache 
relief and time to first become pain free were also analyzed.
Results.—Significantly higher rates of pain freedom (100  mg, 10.0%, P  =  .012; 200  mg, 15.5%, P  <  .001; Placebo, 7.0%) 
and total migraine freedom (100  mg, 8.9%, P  =  .017; 200  mg, 12.4%, P  <  .001; Placebo, 6.1%) were achieved starting at 
60  minutes in 100- and 200-mg lasmiditan-treated groups compared with placebo group. Rates of freedom from most bother-
some symptom (100  mg, 11.1%, P  =  .015; 200  mg, 13.0%, P  <  .001; Placebo, 7.9%), and pain relief (100  mg, 17.5%, 
P  =  .007; 200  mg, 19.1%, P  <  .001; Placebo, 13.4%) were significantly higher starting as early as 30  minutes in lasmiditan 
100- and 200-mg lasmiditan-treated groups. A significantly higher percentage of patients in the 200-mg lasmiditan-treated group 
achieved freedom from photophobia (13.7%, P  =  .005; Placebo, 9.2%) and phonophobia (17.4%, P  =  .042; Placebo, 13.4%) 
starting at 30  minutes. A significantly greater proportion of patients in the 200-mg lasmiditan-treated group achieved freedom 
from migraine-related functional disability starting at 60  minutes (16.4%, P  <  .001; Placebo, 11.1%). All efficacy measures, 
except for freedom from nausea, were statistically significant after lasmiditan treatment (50, 100, or 200  mg) compared with 
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placebo at 90 and 120  minutes. Finally, patients taking lasmiditan had a higher likelihood of achieving meaningful headache 
relief and becoming headache pain free within 24  hours compared with those taking placebo (P  <  .001).
Conclusions.—Patients treated with lasmiditan for a migraine attack reported an earlier onset of efficacy compared with 
those treated with placebo. Some of the efficacy measures such as pain relief demonstrated improvement as early as the first 
assessment at 30  minutes after 100- or 200-mg lasmiditan treatment.
Key words: lasmiditan, migraine, onset of  efficacy, onset of  response, acute treatment, ditan class
Abbreviations:  5-HT 5-hydroxytryptamine, eDiary electronic diary, MBS most bothersome symptom, mITT modified 
ITT, OR odds ratio, TMF total migraine freedom
(Headache 2019;59:1788-1801)
INTRODUCTION
Early relief  of migraine symptoms and related dis-
ability are among the most important and widely mea-
sured benefits of acute migraine treatment.1-3 This has 
been demonstrated in surveys of patients and their cli-
nicians about treatment needs, multi-attribute decision 
modeling, and post hoc analysis of clinical trial data 
examining predictors of satisfaction with treatment 
and willingness-to-pay methods.3-5 Studies assessing 
patients’ preference for migraine medication efficacy 
highlight their desire to have an onset of response 
as early as 30  minutes after an orally administered 
treatment. Moreover, earlier freedom from migraine- 
associated symptoms (phonophobia, photophobia, 
nausea, and vomiting) after treatment is also desired.3,6
Triptans are a class of serotonin 5-hydroxytrypt-
amine 1B/1D (5-HT1B/1D) receptor agonists primarily 
prescribed for the acute treatment of migraine and rep-
resent 28-36% of prescribed medications for the acute 
treatment of migraine.7,8 Triptans are not efficacious 
for all patients.9 Rates of pain freedom at 2 hours after 
dose with triptans in a meta-analysis are between 20 and 
40%.9 Although the introduction of triptans improved 
the acute treatment of migraine, this class of medication 
is not suitable for all patients with migraine. Triptans 
have been known to cause vasoconstriction; therefore, 
they are contraindicated in patients with cardiovascular 
disease and carry warnings and precautions for patients 
with the risk of cardiovascular disease.10
Lasmiditan (LY573144) is a novel therapeutic agent 
designated as a “ditan” in development for the acute 
treatment of migraine.11 The chemical structure and 
5-HT receptor-binding profile of lasmiditan are different 
from that of triptans, making lasmiditan a different class 
of treatment.12 Lasmiditan has high affinity and selec-
tivity for 5-HT1F receptors and lacks the vasoconstric-
tor activity inherent with triptans.13 Lasmiditan efficacy 
and safety are supported by data from the phase 2 and 
phase 3 studies.14-18 Both phase 3 studies, SAMURAI 
and SPARTAN, met primary and key secondary efficacy 
endpoints of statistically significantly higher percentage 
of lasmiditan-treated patients being migraine pain free 
and having freedom from their most bothersome symp-
tom (MBS) at 2 hours following their initial dose com-
pared with patients treated with placebo.16,17
Given the disability associated with the attacks 
and the patients’ needs, it is important to evaluate all 
meaningful efficacy outcomes for acute treatment and 
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the time to achieve those outcomes. To provide com-
prehensive assessment of lasmiditan efficacy in treat-
ing acute migraine attacks, we analyzed the integrated 
data to evaluate the onset of pain freedom, pain relief, 
freedom from migraine-associated symptoms (pho-
tophobia, phonophobia, or nausea), MBS freedom, 
total migraine freedom (TMF), patient reported free-
dom from migraine-related functional disability, and 
patient reported time to meaningful headache relief  
and time to first become headache pain free.19,20 We 
hypothesized that oral lasmiditan would demonstrate 
earlier onset of efficacy than the prespecified 2-hour 
time point for all proposed endpoints.
METHODS
Study Design.—Data from 2 phase 3 studies 
(SAMURAI [27 April 2015-12 August 2016] and 
SPARTAN [19 May 2016-29 June 2017]) were integrated 
for this report. Detailed descriptions of the study design 
for both studies have been reported separately.16,17 
Briefly, SAMURAI and SPARTAN were randomized, 
double-blind, placebo-controlled trials investigating a 
single migraine attack. SAMURAI evaluated 2 doses 
of lasmiditan (100 and 200 mg); SPARTAN evaluated 3 
doses (50, 100, and 200 mg). Patients were randomized 
to either treatment or placebo (1:1:1 and 1:1:1:1, 
respectively). Patients were asked to treat a single 
migraine attack within 4 hours of onset of headache 
(if  the headache severity was at least moderate at that 
time and not improving) within 8 weeks of enrollment.
Trial Population.—Studies SAMURAI and 
SPARTAN were conducted in patients aged 18 years or 
older, diagnosed with migraine based on the Interna-
tional Classification of Headache Disorders-II, with a 
history of migraine for at least 1 year, and with migraine 
onset before the age of 50. Eligible participants had 
to experience 3-8 migraine attacks per month (<15 
headache days per month) during the baseline period. 
Participants were also required to have a Migraine 
Disability Assessment score  ≥  11. Patients on stable 
doses of concomitant migraine preventive medications 
were allowed in the studies. Patients with cardiovascular 
risk factors were permitted in both the studies. 
Further inclusion and exclusion criteria have been 
discussed previously.16,17 The participating sites for the 
studies were located in the United States, the United 
Kingdom, and Germany. Subjects were randomized 
through a central randomization process by Interactive 
Response Technology during screening/Visit 1.
Outcome Measures.—Electronic diary (eDiary) 
was used to collect data at baseline and at 30-minute 
intervals up to 48 hours after treatment. The analyses 
presented used data collected at baseline, and 
data collected at 30, 60, 90, and 120 minutes after 
treatment. The intent-to-treat (ITT) population inclu-
ded all randomized patients who took at least 1 dose 
of study drug and had any post-dose headache severity 
or symptom assessments. The modified ITT (mITT) 
population included all ITT patients who treated a 
migraine attack within 4  hours of migraine attack 
onset. The mITT population data were used to perform 
all analyses, except for pain relief. Even though patients 
were asked to take the medication if their headache 
severity was at least moderate, 1.7% of patients who 
reported taking the medication while experiencing mild 
headache were also included in the analyses.
The efficacy outcomes evaluated were pain free-
dom, pain relief, freedom from MBS, freedom from 
other migraine-associated symptoms (photophobia, 
phonophobia, or nausea), patient-reported freedom 
from migraine-related functional disability, TMF, time 
to meaningful headache relief, and time to first be-
come headache pain free. Patients recorded migraine 
headache pain using a 4-point International Headache 
Society pain severity rating scale (none, mild pain, mod-
erate pain, and severe pain). Pain freedom was defined 
as a reduction in pain severity from mild, moderate, or 
severe at baseline to none at the specified time point. 
Pain relief  was defined as experiencing moderate or se-
vere pain at baseline that became mild or none, or mild 
pain at baseline that became none at the summarized 
time point.1,17 The presence or absence of migraine- 
associated symptoms (photophobia, phonophobia, and 
nausea) was recorded at baseline. Freedom from these 
associated symptoms at summarized time points was 
analyzed in patients who reported the respective symp-
tom at baseline. In addition, patients were instructed 
to record their selection of which of the accompanying 
symptoms (nausea, phonophobia, and/or photopho-
bia) was the MBS. Freedom from MBS was defined 
as the absence of the selected MBS at subsequent time 
points. The patients were defined as having TMF at a 
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given time point if  they were experiencing pain freedom 
and not experiencing any other migraine symptoms (ie, 
not experiencing nausea, photophobia, or phonopho-
bia).21 This measurement better addresses the patient’s 
needs to be free from all migraine symptoms, not only 
headache pain. The degree of migraine-related func-
tional disability was recorded in the eDiary as the 
response to “How much is your migraine interfering 
with your normal activities?”. Responses were recorded 
on a 4-point numeric rating scale: not at all, mild inter-
ference, marked interference, and need complete bed 
rest.16 Freedom from migraine-related functional dis-
ability was defined as having disability “None” at a given 
time point.
In addition, participants were asked to record in 
the eDiary the time at which headache relief became 
meaningful and time they became headache pain free. 
Patients were asked, “Has headache relief become 
meaningful?” (responded with “Yes” or “No”). If  the 
patients responded “Yes” they were asked “Have you 
been headache pain free?” (responded with “Yes” 
or “No”). Patients censored were those that did not 
report experiencing the event of interest after treatment 
and did not use the eDiary within 24 hours after treat-
ment. These patients were censored at their time of last- 
reported eDiary use. Finally, for these analyses, subjects 
were censored at 24 hours if  they reported experiencing 
the event of interest more than 24 hours after taking 
the treatment or did not report experiencing this event.
Statistical Analysis.—Odds ratios (ORs) were 
used to quantify association between the efficacy 
measures of interest and lasmiditan treatment. For 
comparisons between treatment groups, the OR, its 
P value, and asymptotic confidence interval were 
calculated from a 2-sided test from a logistic regression 
model with treatment group, study, and background 
use of migraine preventive medication as covariates. 
Due to post hoc nature of these analyses, P values are 
reported without multiplicity correction. A P value 
<.05 was considered statistically significant. The 
sample size estimation for each study has been 
published previously.16,17 Additionally, the number 
needed to treat (NNT) was calculated for several 
endpoints. NNTs were calculated as the inverse of the 
difference between the odds ratios of lasmiditan and 
placebo treatment arms at 2 hours post dose.
For pain freedom, pain relief, freedom from MBS, 
and freedom from other migraine-associated symptoms 
(photophobia, phonophobia, or nausea) endpoints 
denominators for calculating percentages are the counts 
of symptomatic subjects, defined as those experiencing 
the symptoms of interest at baseline. Denominators for 
calculating onset of TMF percentages are the counts 
of subjects with mild, moderate, or severe headache 
pain recorded at the time of dosing. Denominators for 
calculating migraine-related functional disability per-
centages are the counts of subjects in the mITT pop-
ulation for each treatment arm. Patients with missing 
data were treated as nonresponders for their missing 
time point values.
Output from SAS PROC LIFETEST Kaplan-
Meier product limit method was used for plotting the 
cumulative probability curves in the time to meaning-
ful headache relief, and time to first become headache 
pain-free figures. A stratified log-rank test for homo-
geneity of the curves stratified by treatment was con-
ducted for each time to event endpoint.
SAS Enterprise Guide 7.1 (SAS Institute, Cary, 
NC) statistical package was use for analyses.
All authors had full access to all study data and 
had final responsibility for the decision to submit for 
publication.
Ethical Conduct of the Studies.—These studies were 
reviewed and approved by appropriate institutional 
review boards and were conducted according to the 
Declaration of Helsinki. The participants signed an 
informed consent document approved by each study 
site’s independent ethics committee or institutional 
review board before any study-related procedures 
were performed.
RESULTS
Patient Demographics and Baseline Disease Charac-
teristics.—The study population (all randomized 
patients) included patients with an average age of 
42 years, mostly female (83%), and white (77%) (Table 1). 
The composition of the study population was 
similar to that of the U.S. population in terms of 
race and ethnicity (white, 77%; black, 19%; Hispanic, 
18%). A total of 5236 patients were randomized 
to be treated with placebo (N  =  1493), lasmiditan 
50 mg (N = 750), lasmiditan 100 mg (N = 1498), or 
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lasmiditan 200 mg (N = 1495). A total of 1301 patients 
treated with placebo and 3235 patients treated with 
lasmiditan completed the study. The baseline disease 
characteristics are presented in Table 1. All baseline 
disease characteristics had a similar percentage of 
patients in each study.
Pain Freedom and Pain Relief.—A significantly 
higher percentage of patients treated with 100- and 
200-mg lasmiditan achieved pain freedom 60 minutes 
after treatment compared with the placebo group 
(Placebo, 7.0%; 100  mg, 10.0%, P = .012; 200  mg, 
15.5%, P < .001; Fig. 1 and Table 2). Patients treated 
with 50-mg lasmiditan achieved pain freedom 
90  minutes after treatment (Placebo, 11.9%; 50  mg, 
18.0%, P =  .012). The NNT to achieve pain freedom 
120 minutes after treatment and relative to placebo for 
50 mg is 10, 9 for 100 mg, and 6 for 200 mg. As early 
as 30 minutes after treatment with lasmiditan 100 and 
200  mg, a significantly higher percentage of patients 
achieved pain relief  (Placebo, 13.4%; 100 mg, 17.5%, 
P = .007; 200 mg, 19.1%, P = .001; Fig. 1 and Table 2), 
while treatment with 50  mg of lasmiditan achieved 
pain relief at 60 minutes compared with patients in the 
placebo group (Placebo 30.6%; 50 mg, 37.3%, P = .023). 
The NNT to achieve pain relief  120  minutes after 
treatment and relative to placebo for 50 mg is 7, 6 for 
100 mg, and 6 for 200 mg.
There was a significant difference in onset of 
pain freedom and pain relief  between lasmiditan 
dose groups. Patients treated with 200-mg lasmiditan 
experienced a significant pain freedom 60  minutes 
after treatment compared with 50- and 100-mg las-
miditan-treated groups (50 mg, P < .001, OR = 2.59 
[1.78, 3.78]; 100  mg, P  <  .001, OR  =  1.65 [1.26, 
2.14]). Pain relief  was experienced by 200-mg las-
miditan-treated patients 60  minutes after treatment 
compared with 50-mg lasmiditan-treated patients, 
whereas there was no difference with 100-mg lasmid-
itan-treated patients (50  mg, P  <  .001, OR  =  1.46 
[1.18, 1.81]).
Table 1.—Patient Demographics and Baseline Disease Characteristics
SAMURAI (N = 2231) SPARTAN (N = 3005) Pooled (N = 5236)
Age, mean (SD) 42 (12.17) 42 (12.93) 42 (12.62)
% Female 82.6 83.7 83.2
% Caucasian 74.4 78.9 77.1
% Black 20.4 17.4 18.7
Ethnicity, n (%)
Hispanic or Latino 303 (13.6) 610 (20.3) 913 (17.5)
Not Hispanic or Latino 1913 (85.70) 2373 (79.00) 4286 (82.0)
Not reported 13 (0.6) 10 (0.3) 23 (0.4)
Unknown 2 (0.1) 5 (0.2) 7 (0.1)
Duration of migraine history, years, mean (SD) 18.9 (13.02) 18.1 (12.97) 18.46 (13.0)
Migraines per month in past 3 months, mean (SD) 5.1 (1.89) 5.3 (2.06) 5.2 (1.99)
MIDAS total score, mean (SD) 31.3 (22.33) 32.5 (23.57) 31.94 (22.79)
Days with headache in past 3 months, mean (SD) 17.3 (10.76) 17.4 (10.46) 17.39 (10.41)
Baseline-associated symptoms, n (%) N = 1545 N = 2156 N = 3701
Photophobia 1193 (77.2) 1649 (76.5) 2842 (76.8)
Phonophobia 952 (61.6) 1354 (62.8) 2306 (62.3)
Nausea 663 (42.9) 948 (44.0) 1611 (43.5)
Baseline-associated symptoms identified as MBS, 
n (%)
N = 1545 N = 2156 N = 3701
Photophobia 773 (50.0) 1090 (50.6) 1863 (50.3)
Phonophobia 317 (20.5) 447 (20.7) 764 (20.6)
Nausea 348 (22.5) 472 (21.9) 820 (22.2)
Duration of migraine history and frequency of migraine attacks in the last 3 months were measured from the date of Visit 1. MIDAS 
total score is calculated as the sum of the answers to the 5 questions on the MIDAS questionnaire.
MBS = most bothersome symptom; MIDAS = Migraine Disability Assessment; n = number of patients within each specific category; 
N = total number of patients; SD = standard deviation.
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Migraine-Associated Symptoms and Most Bothersome 
Symptom Freedom.—The results for freedom from 
migraine-associated symptoms and MBS are presented 
in Fig. 2 and Table 3. As early as 30  minutes after 
dosing, patients treated with 200-mg lasmiditan 
achieved a significant photophobia freedom compared 
with placebo (Placebo, 9.2%; 200 mg, 13.7%, P = .005). 
Patients treated with 50- and 100-mg lasmiditan 
achieved photophobia freedom 60 minutes after dosing 
compared with placebo (Placebo, 18.0%; 50  mg, 
23.7%, P =  .045; 100 mg, 28.7%, P <  .001). Patients 
treated with 200, and 100 mg achieved phonophobia 
Fig. 1.—Percentage of patients experiencing (A) pain freedom and (B) pain relief. ***P ≤ .001; **P ≤ .01; *P ≤ .05 vs placebo. [Color 
figure can be viewed at wileyonlinelibrary.com]
Table 2.—Odds Ratio of  Patients Experiencing Pain Freedom and Pain Relief
Time After 
Dose (min)
Placebo LTN 50 mg LTN 100 mg LTN 200 mg
n % n OR (95% CI) n OR (95% CI) n OR (95% CI)
N = 1063 N = 556 N = 1035 N = 1046
Pain freedom 30 15 1.4 11 1.38 (0.60, 3.15) 16 1.10 (0.54, 2.23) 25 1.71 (0.90, 3.27)
60 74 7.0 40 0.94 (0.63, 1.43) 104 1.49 (1.09, 2.03)*** 162 2.45 (1.83, 3.27)*
90 127 11.9 100 1.46 (1.09, 1.97)*** 216 1.94 (1.53, 2.46)* 280 2.70 (2.14, 3.40)*
120 195 18.3 159 1.57 (1.22, 2.02)* 309 1.89 (1.54, 2.33)* 372 2.47 (2.02, 3.02)*
N = 1129 N = 598 N = 1133 N = 1120
Pain relief 30 151 13.4 93 1.21 (0.90, 1.62) 198 1.37 (1.09, 1.72)** 214 1.53 (1.22, 1.92)*
60 346 30.6 223 1.29 (1.04, 1.61)*** 467 1.59 (1.33, 1.89)* 509 1.89 (1.59, 2.24)*
90 464 41.1 297 1.31 (1.07, 1.62)*** 619 1.73 (1.46, 2.04)* 627 1.83 (1.54, 2.16)*
120 508 45.0 353 1.58 (1.27, 1.95)* 704 2.01 (1.70, 2.38)* 697 2.02 (1.71, 2.40)*
*P < .001.
**P < .01.
***P < .05 compared with placebo.
CI = confidence interval; LTN = lasmiditan; min = minutes; n = number of patients within each specific category; N = total number 
of patients; OR = odds ratio.
November/December 20191794
freedom 30 and 60 minutes after dosing, respectively, 
relative to placebo (Placebo 13.4%, 200  mg, 17.4%, 
P  =  .042; Placebo 25.7%, 100  mg, 33.0%, P  =  .004). 
None of the treatment groups achieved a significant 
freedom from nausea. Comparison among lasmiditan-
treated groups showed a significance in achieving 
photophobia freedom in patients treated with 200- and 
100-mg lasmiditan, compared with 50-mg treatment 
group, 30 and 60 minutes after treatment, respectively 
(200 mg, P  =  .015, OR  =  1.65 [1.10, 2.46]; 100  mg, 
P  =  .044, OR  =  1.34 [1.01, 1.79]). There was no 
difference among lasmiditan-treated groups in regard 
to phonophobia freedom.
A significantly higher percentage of patients 
treated with 100- and 200-mg lasmiditan achieved 
freedom from MBS 30 minutes after treatment relative 
to placebo (Placebo 7.9%; 100  mg, 11.1%, P  =  .015; 
200 mg, 13.0%, P < .001). Patients treated with 50-mg 
lasmiditan achieved freedom from MBS at 120  min-
utes (Placebo 31.5%; 50  mg, 40.8%, P  =  .012). The 
NNT to achieve freedom from MBS 120 minutes after 
Fig. 2.—Percentage of patients experiencing freedom from (A) photophobia, (B) phonophobia, (C) nausea, and (D) MBS. 
***P ≤ .001, **P ≤ .01, *P ≤ .05 vs placebo. MBS = most bothersome symptom (nausea, phonophobia, and/or photophobia) selected 
by the patient. [Color figure can be viewed at wileyonlinelibrary.com]
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treatment and relative to placebo for 50 mg is 11, 9 for 
100 mg, and 8 for 200 mg.
Total Migraine Freedom.—TMF was achieved by 
patients receiving 100- and 200-mg lasmiditan 60 min-
utes after treatment compared with patients in the 
pla cebo group (Placebo, 6.1%; 100 mg, 8.9%, P = .017; 
200 mg, 12.4%, P < .001; Fig. 3 and Table 4). Patients 
treated with 50-mg lasmiditan achieved TMF 90 minutes 
after treatment (Placebo 10.3%; 50 mg, 16.5%, P = .002; 
Fig. 3 and Table 4). The NNT to achieve TMF 
120 minutes after treatment and relative to placebo for 
50 mg is 11, 10 for 100 mg, and 7 for 200 mg. Comparison 
among lasmiditan-treated groups showed that patients 
treated with 200 mg of lasmiditan were more likely to 
achieve TMF at 60  minutes after treatment compared 
with patients treated with 50- and 100-mg lasmiditan 
(50  mg, P  <  .001, OR  =  2.23 [1.49, 3.33]; 100  mg, 
P = .009, OR = 1.46 [1.10, 1.93]).
Freedom From Migraine-Related Functional 
Disability.—Patients treated with 200 mg of lasmiditan 
achieved freedom from migraine-related functional 
disability 60 minutes after treatment (Placebo, 11.1%; 
200  mg, 16.4%, P  <  .001; Fig. 3 and Table 4), while 
patients treated with 50- and 100-mg lasmiditan 
achieved freedom from migraine-related functional 
disability 90  minutes after treatment compared with 
patients who received placebo (Placebo, 16.8%; 50 mg, 
22.3%, P =  .031; 100 mg, 24.8%, P <  .001; Table 4). 
Comparison among lasmiditan-treated groups showed 
that patients treated with 200 mg of lasmiditan were 
more likely to achieve freedom from migraine-related 
functional disability 60  minutes after treatment com-
pared with the 50-mg treatment group (P  =  .019, 
OR = 1.47 [1.07, 2.03]).
Time to Meaningful Headache Relief and Time 
to Become Headache Pain Free.—The cumulative 
probability of achieving meaningful headache relief  
was higher for patients in all lasmiditan-treated groups 
compared with placebo 24  hours after treatment 
(Fig. 4, P < .001). The time to become headache pain 
free after treatment was reduced in lasmiditan-treated 
patients compared with placebo within 24 hours after 
treatment for all lasmiditan-treated groups (Fig. 5, 
P < .001). A dose-response was observed with a greater 
probability of reaching meaningful headache relief  and 
becoming headache pain free when treated with higher 
doses of lasmiditan.
DISCUSSION
In this integrated report of efficacy from 2 clini-
cal studies, we have presented data showing that pa-
tients treated with lasmiditan for a single migraine 
attack reported an earlier onset of efficacy compared 
with patients who received placebo in measures of pain 
freedom, freedom from MBS, pain relief, photophobia 
freedom, phonophobia freedom, TMF, freedom from 
Fig. 3.—Percentage of patients (A) Experiencing total migraine freedom and (B) Freedom from migraine-related functional disability. 
***P ≤ .001, **P ≤ .01, *P ≤ .05 vs placebo. [Color figure can be viewed at wileyonlinelibrary.com]
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migraine-related functional disability, time to mean-
ingful headache relief, and time to first become head-
ache pain free.
Previously, it has been reported that SAMURAI 
and SPARTAN studies met primary and key secondary 
efficacy endpoints for all doses (50, 100, and 200 mg) 
2  hours after treatment with lasmiditan.16,17 The re-
sults from the post hoc analyses presented here sup-
port and expand upon those findings. Treatment with 
lasmiditan achieved freedom from MBS, pain relief, 
Fig. 4.—Time to meaningful headache relief: Cumulative probability of experiencing meaningful headache relief after treatment. 
[Color figure can be viewed at wileyonlinelibrary.com]
Fig. 5.—Time to first become headache pain free. [Color figure can be viewed at wileyonlinelibrary.com]
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photophobia freedom, phonophobia freedom, and 
freedom from migraine-related functional disability 
as early as 30 minutes after treatment compared with 
placebo. Lasmiditan treatment also showed benefits 
over placebo at 60 minutes in terms of percentage of 
patients who were pain free, and experiencing TMF. 
The time to experiencing meaningful headache relief, 
and becoming headache pain free is earlier between 
0 and 24  hours after treatment with lasmiditan over 
those treated with placebo. Overall, treatment with 
lasmiditan resulted in an earlier onset of efficacy com-
pared with placebo. Lasmiditan onset of pain response 
is comparable to the onset of efficacy of oral triptans, 
which is between 30 and 120 minutes after treatment. 
However, direct comparison to triptans is limited by 
differences in study design, patient populations, and 
triptan formulations.22-32 Moreover, there are limited 
data available on the onset of all outcomes measured 
in this report for triptans.
A comprehensive endpoint, TMF, was assessed 
in these post hoc analyses. Total migraine freedom is 
defined as experiencing pain freedom and freedom 
from other migraine-associated symptoms. These out-
comes are usually measured independently, which lim-
its the understanding of the overall effect of a therapy. 
Patients who are experiencing pain freedom could still 
be experiencing migraine-associated symptoms, which 
could impact their migraine-related functional dis-
ability during an attack. In these pooled analyses, we 
are able to show that a greater proportion of patients 
treated with lasmiditan (100 and 200  mg) achieved 
TMF as early as 60 minutes after treatment compared 
with patients who received placebo.
Given that migraine is associated with significant 
disability, it is important to have a migraine ther-
apy that effectively mitigates the negative impact of 
migraine attacks on daily life. Freedom from migraine- 
related functional disability was achieved by patients 
treated with lasmiditan (200  mg) in greater propor-
tion than by patients treated with placebo as early as 
60 minutes after treatment.
Lasmiditan was associated with neurologic TEAEs, 
which were mostly mild or moderate in severity, 
self-limiting, and of short duration.18 It is possible that 
these TEAEs could interfere with efficacy assessments. 
However, 2  hours posttreatment efficacy outcomes 
following lasmiditan treatment such as pain freedom, 
freedom from MBS, patient reported migraine-related 
functional disability and global impression of change 
in patients with presence or absence of these common 
TEAEs’ were comparable.18
A limitation of these pooled analyses include that 
the first post dose assessment occurred 30  minutes 
after treatment and it is possible that onset of efficacy 
for some outcomes measured may have been sooner 
than 30 minutes. These are post hoc analyses and the 
efficacy outcomes TMF, time to meaningful head-
ache relief, time to first become headache pain free 
and comparisons between treatment groups were not 
prespecified before examining the data. In addition, 
multiple analyses of efficacy were conducted without 
correction for multiplicity. Also, the SPARTAN study 
was the only study evaluating a 50-mg dose of lasmidi-
tan; thus, we had a lower number of participants in the 
50-mg lasmiditan-treated group.
In conclusion, these integrated pooled analyses 
show that lasmiditan-treated patients experience ear-
lier pain freedom, freedom from MBS, pain relief, 
freedom from migraine-associated symptoms, TMF, 
freedom from migraine-related functional disability, 
time to meaningful headache relief, and time to first 
become headache pain free than those treated with 
placebo. These results suggest that lasmiditan has 
demonstrated early efficacy as an acute treatment for 
migraine attacks.
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